Regeneron reported strong Q3 2024 results with total revenue up 11% to $3.72 billion. Dupixent global net sales surged 23% to $3.82 billion, while U.S. EYLEA HD and EYLEA sales rose 3% to $1.54 billion. Libtayo global net sales increased 24% to $289 million.GAAP diluted EPS grew 30% to $11.54, and non-GAAP diluted EPS rose 8% to $12.46. The quarter included a $0.43 impact from an acquired IPR&D charge. R&D expenses increased 18% to $1.27 billion as the company advanced its clinical pipeline, including late-stage oncology programs.Regeneron achieved significant milestones, including FDA approval of Dupixent for COPD and positive results in chronic spontaneous urticaria and bullous pemphigoid trials. The company maintains a strong financial position with $18.3 billion in cash and marketable securities as of September 30, 2024.

Regeneron reported strong Q3 2024 results with total revenue up 11% to $3.72 billion. Dupixent global net sales surged 23% to $3.82 billion, while U.S. EYLEA HD and EYLEA sales rose 3% to $1.54 billion. Libtayo global net sales increased 24% to $289 million.GAAP diluted EPS grew 30% to $11.54, and non-GAAP diluted EPS rose 8% to $12.46. The quarter included a $0.43 impact from an acquired IPR&D charge. R&D expenses increased 18% to $1.27 billion as the company advanced its clinical pipeline, including late-stage oncology programs.Regeneron achieved significant milestones, including FDA approval of Dupixent for COPD and positive results in chronic spontaneous urticaria and bullous pemphigoid trials. The company maintains a strong financial position with $18.3 billion in cash and marketable securities as of September 30, 2024.